Literature DB >> 1394168

Molecular basis of lymphomagenesis.

I Magrath1.   

Abstract

Lymphoid neoplasms, like all malignant tumors, arise as a consequence of the accumulation, in a single cell, of a set of genetic lesions that result in altered proliferation or increased clonal life span. The most frequently observed genetic abnormalities among the malignant non-Hodgkin's lymphomas are translocations, which appear to be lineage and, to a large extent, lymphoma specific. Recombinases that normally mediate the process of antigen receptor gene rearrangement appear to have an important (but not exclusive) role in the mediation of these translocations and of other types of gene fusion (e.g., deletion of intervening DNA). Frequently, such fusions result in the increased or inappropriate expression of crucially important proteins, many of which are transcription factors that regulate the expression of other genes. These abnormalities, however, do not appear to be sufficient to induce lymphoma, and it is likely that the additional genetic lesions required differ from one tumor to another. The likelihood of any given clone of cells accumulating a sufficient number of relevant genetic lesions to give rise to a lymphoma is probably a function of its life span. Prolonged survival of a cell clone may be mediated by viral genomes (e.g., Epstein-Barr virus and human T-cell leukemia/lymphoma virus type 1), by the abnormal expression of cellular genes that inhibit apoptosis (e.g., bcl-2), or by the mutation or deletion of cellular genes that are necessary for apoptosis, e.g., p53. The background rate at which genetic lesions occur is amplified by the interaction of inherited and environmental factors, the latter appearing to be the major determinant of incidence rates. However, inherited factors that influence lymphomagenesis, including variability in the ability to repair DNA damage or in the fidelity of antigen receptor recombinases for their signal sequences, may be crucial determinants of which particular individuals in a given environmental setting develop lymphoma.

Entities:  

Mesh:

Year:  1992        PMID: 1394168

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.

Authors:  Yuko Hirose; Yasufumi Masaki; Hiromi Karasawa; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Mamoru Ozaki
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Histamine content in lymph nodes from patients with malignant lymphomas.

Authors:  A Belcheva; R Mishkova
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

Review 4.  The search for a gene involved in the determination of limited duplicative capacity in human cells.

Authors:  E Calef; A Scotto d'Abusco; E Bianchi; S Gargano; A Fruscalzo
Journal:  Genetica       Date:  1994       Impact factor: 1.082

5.  A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?

Authors:  G Enblad; K Carlson; M Bengtsson; H Hagberg
Journal:  Med Oncol       Date:  2000-08       Impact factor: 3.064

6.  Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma.

Authors:  Hong-Wei Zhang; Niu-Liang Cheng; Zhen-Wen Chen; Jin-Fen Wang; Su-Hong Li; Wei Bai
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

7.  Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations.

Authors:  A Y Matsushima; E Cesarman; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

8.  Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.

Authors:  Cindy M Chang; Jane C Schroeder; Wen-Yi Huang; Cherie H Dunphy; Ralph S Baric; Andrew F Olshan; Kathleen C Dorsey; Georgette A Dent; James R Cerhan; Charles F Lynch; Nathaniel Rothman; Kenneth P Cantor; Aaron Blair
Journal:  Leuk Res       Date:  2009-06-07       Impact factor: 3.156

9.  BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.

Authors:  Javeed Iqbal; Warren G Sanger; Douglas E Horsman; Andreas Rosenwald; Diane L Pickering; Bhavana Dave; Sandeep Dave; Li Xiao; Kajia Cao; Quiming Zhu; Simon Sherman; Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; German Ott; H Konrad Müller-Hermelink; Jan Delabie; Rita M Braziel; Elaine S Jaffe; Elias Campo; James C Lynch; Joseph M Connors; Julie M Vose; James O Armitage; Thomas M Grogan; Louis M Staudt; Wing C Chan
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis.

Authors:  J L Gala; C Vermylen; G Cornu; A Ferrant; J L Michaux; M Philippe; P Martiat
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.